New drug delivery methods tested for tough breast cancer
NCT ID NCT07560475
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called SHR-A1811 in 60 adults with HER2-positive advanced breast cancer who have had up to 2 prior treatments. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The main goal is to measure how many patients have their tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Insititute and Hospital
Tianjin, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Can an oral chemo pill boost breast cancer treatment?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?